MOMOPro Posted - 4 days ago

In case sleeping AH $VKTX on news. Looks like a Nash drug. Unsure how the results compare vs. old fav $ICPT and others, but catching a bid.

hashtagzee Posted - 4 days ago

$AUPH Feels eerily similar to another buyout I wasn’t apart of but had on my radar, $ICPT. Nothing but good news flooding the market, major layoffs and then BOOM. Cautiously optimistic with PG still in charge but my sentiment still remains BULLISH. LFG

rencofilstat Posted - 1 week ago

$ICPT what is this trash?

Article_AI Posted - 1 week ago

$ICPT US FDA declines full approval for Intercept's liver disease drug The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, raising questions about its future in the market. https://www.stck.pro/news/ICPT/93006340/

rencofilstat Posted - 1 month ago

$ICPT how is this shit not shut down already?, meanwhile $hepa has the best results for liver stiffness and is in the gutter.

Wildcat63 Posted - 1 month ago

$AUPH @US_Bull you said $AUPH is similar to $ICPT. A couple of points. $ICPT had a single pipeline. They were sold at $19 per share with around 48 million outstanding shares. At the time of their BO announcement, they had pulled back all other drug studies and were considering to downsize their headcount to conserve cash. The first half sales were $152 million. To compare $AUPH to this means that their cash flow positive plus available cash reserve would offset 15 million shares. The remaining shares would mean a buyout at a little over $2.5B to achieve $19 per share target. Check my math!

Article_AI Posted - 2 months ago

$ICPT FDA advisers vote against confirmatory data for Intercept's liver disease drug Independent advisers to the U.S. Food and Drug Administration voted on Friday against confirmatory trial data for Intercept Pharmaceuticals' liver disease drug, putting into question the treatment's future in the U.S. market. https://www.stck.pro/news/ICPT/89112092/

DoctrBenway Posted - 2 months ago

$ICPT So glad we got bought, even slightly below my basis, given new problems at FDA. [No longer trading, acquired.]

Article_AI Posted - 2 months ago

$ICPT FDA staff raises efficacy concerns over Intercept's liver disease drug The U.S. Food and Drug Administration's staff on Wednesday raised concerns over the efficacy of Intercept Pharmaceuticals' liver disease drug, which is awaiting the regulator's traditional approval. https://www.stck.pro/news/ICPT/88941814/

Goldilockszone69 Posted - 08/25/24

$TNXP well, a lot of you might not remembering when $JAZZ Pharmaceuticals was trading under .50 cents but I do. Tonix has backing from Institutional Investors Ultimately the FDA decides the price for $TNXP. The NDA Filing for Tonmya and FAST Track status granted the clock is ticking towards approval p value = .00005. Once the NDA is submitted could be approved in 6 months of at FDA's discretion. Intercept Pharmaceuticals was another one $ICPT that took off and hit $400 share. So do your own research. $TNXP 1) NDA Filing soon for Tonmya 2) TNX 801 viral "Clearly more testing is ahead for TNX-801" FDA Fast Track designation Granted to TNX-102 SL 3) TNX 1300 Clinical Trial Cocaine : Phase IIb TNX-1300’s development is being supported by the National Institutes of Health (NIH), according to Tonix. The asset has also been granted breakthrough therapy designation by the US Food and Drug Administration (FDA). 4) TNX 4200 The $34 million, five-year contract will help bankroll research

hashtagzee Posted - 3 months ago

$AUPH I will say that all of the moves made since the last ER are eerily similar to Intercept Pharma ($ICPT) before it got bought out. They cut headcount, cleared the pipeline (AUR200 mention last ER still odd, could be another bluff), got cash flow positive and then essentially forced themselves onto BP. I wouldn’t expect more than $10-$12 if it ever happens under current conditions. Still, this move is likely tied to one of three things 1) OPEX 2) incoming PG resignation 3) Possible Japan approval (the market Otsuka actually cares the most about) Still… if it drops back to $5.50 on Monday, NOBODY is going to be surprised.

NVDAMillionaire Posted - 3 months ago

$ICPT Intercept Pharmaceuticals, Inc. (ICPT): Navigating the Complexities of Rare and Serious Liver Diseases http://beyondspx.com/2024/08/05/intercept-pharmaceuticals-inc-icpt-navigating-the-complexities-of-rare-and-serious-liver-diseases/

Blackhole_1987 Posted - 4 months ago

$AUPH. $ICPT management who were awarded RSUs on 05/24 held their shares until the company was BO in sep 2023. But that's not the case with $AUPH, PG and others immediately exercised at a price below $6 in Feb or Mar 2024. Does this give any indication that a BO is not anytime soon as they would have expected the SP to go further south?.

BearBullyJack Posted - 06/27/24

@BlakeCanyon50 look at $ICPT history with the FDA. FDA was ICPT’s fan girl over their first in class MASH drug giving them fast track approval, cruised them through to Phase 3, received results and vomited over their tolerability results and denied them. $ALT has deplorable tolerability data compared to $VKTX damn near perfect tolerability in the obesity space.

huntthepermabulls Posted - 5 months ago

$ICPT $TENX $VRAX $GOVX $AEMD bird flu stocks to the moon

Stock_Titan Posted - 6 months ago

$ICPT Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference https://www.stocktitan.net/news/ICPT/intercept-announces-new-pbc-data-analyses-to-be-presented-at-5m0thl79tv7m.html

fatsmitch Posted - 7 months ago

$ICPT what is this stock doing its just always at $19

DontBadgerMe Posted - 8 months ago

$NDRA $VKTX $MDGL $ICPT go to the Echosens website.and look at the global FibroScan locator and you'll see how far behind Endra is

BearBullyJack Posted - 8 months ago

$NDRA can someone get me up to speed? Had an investment in this 4 years ago and sold after a small gain because wasn’t getting the price movement I was hoping for from positive results from $VKTX $MDGL, and at the time $ICPT. What reason has this not taken off? Approval in EU, alternative to biopsies? Faster diagnosis? I just can’t wrap my mind around it but maybe someone can get me up to speed as I have not followed it for years now. Looking to jump back in, thanks

TraderLawJCF Posted - 8 months ago

$MDGL Where’s the fraud CEO of $ICPT from 2014 thinking he had miracle rejecting b/o offers…selling shared every year…on his yacht

BearBullyJack Posted - 8 months ago

$MDGL $VKTX I’ve seen these guys grow nearly from their infancy. My conviction has remained strong through and through and given the data provided over the last few years and in comparison to others in this space, particularly $ICPT FDA review, Madrigal will surely be approved and sell well. Viking will have a good chance to share that market share and be a menace when it too reaches the market for sales but Madrigal has a solid 2 years to make a mark in their market share and get real sale numbers up. Hold strong folks, this one has room to grow $400+ and Viking at $150+ especially given their GLP-1 and the not so known but absolutely freakishly good drug VK5211

All_just_a_game Posted - 8 months ago

$MDGL This is from 2016 when I acquired my MDGL stake via Synta. Thank god Becky was shagging Paul and they merged companies otherwise I would have been a permanent bankrupt bag holder. 8 years later.. ICPT GILD Genfit. Failed. Madrigal..2 weeks from being only approved therapy. ☘️ ☘️☘️☘️☘️☘️GL After PhIII failure Synta announces merger, shifts R&D focus By Ben Adams Apr 14, 2016 9:53am Synta joins a long and growing list of biotechs and pharma moving in on the NASH space, which analysts believe could be worth $40 billion in the next decade. Intercept ($ICPT), Gilead ($GILD) and French biotech Genfit are just some of the players in this emerging field which aim to develop the first ever treatments for the liver scarring disease--a disease caused predominately by the rising rates of obesity and diabetes.

Stock_Titan Posted - 02/29/24

$ICPT Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC https://www.stocktitan.net/news/ICPT/intercept-announces-fda-acceptance-of-supplemental-new-drug-r05mdkc22mni.html

GSMITH10107 Posted - 9 months ago

$IVA is it possible $IVA could potentially be the leader in NASH ? i know $ICPT got bought out and $MDGL is launching this year, but thsi graphic has to mean alot..

GSMITH10107 Posted - 9 months ago

$IVA 194 million dollar market cap.. well into phase 3 compared to NASH players $ICPT bought out for 795 million $MDGL 4.1 billion $AKRO 1.1 billion pretty shocking graphic if you ask me when do i get my correction?

MMCT Posted - 9 months ago

$MDGL @@All_just_a_game @CC_Abbott Could u both point out on a comment why $ICPT got rejected by Adcom and why We have a better chance 😄

bbear Posted - 9 months ago

$ICPT never forget some assclown at BOA slapped a $800 PT on this in 2014. she then left BOA to work for the company.